Tumor burden influences prognosis in lymphoma, with unidimensional bulk used for risk assessment and decisions about radiotherapy consolidation ([1][1]). Total metabolic tumor volume (TMTV) using 18F-FDG PET emerged 10 y ago as a promising biomarker ([2][2]) that was superior to bulk ([3][3]).
No takes yet. Share an insight, caveat, or question.
Barrington et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: